Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients

Conclusion:
Spironolactone treatment in hemodialysis patients was secure and effective in regression of left ventricular hypertrophy, a major risk factor for cardiovascular events in these patients. This effect occurred in spite of blood pressure stability.

Trial registration:
ClinicalTrials.gov identifier NCT01128101

Source: Therapeutic Advances in Cardiovascular Disease - September 2, 2015 Category: Cardiology Authors: Feniman-De-Stefano, G. M. M., Zanati-Basan, S. G., De Stefano, L. M., Xavier, P. S., Castro, A. D., Caramori, J. C. T., Barretti, P., Jorge da Silva Franco, R., Martin, L. C. Tags: Original Research Source Type: research